Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-9911 as Monotherapy and in Combination With Zimberelimab in Adults With Advanced Solid Tumors
NCT06082960Phase 1Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of GS-9911 in solid tumor (4 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants With Treatment-emergent Adverse Events up to 105 weeks, Percentage of Participants With Treatment-emergent Serious Adverse Events up to 105 weeks and 1 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
GS-9911
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06082960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06082960.